De novo pemphigus vulgaris and pemphigus foliaceus development following COVID-19 infection and vaccination: Matched case-control study

Affiliations

¹ Department of Surgical Science, University of Turin, Turin, Italy.
² State Research Center of Dermatovenereology and Cosmetology, Moscow, Russian Federation.
³ Sechenov First Moscow State Medical University, Moscow, Russian Federation.
⁴ Department of Public Health and Infectious Diseases, Sapienza University, Rome, Italy.

P G Arduino et al. J Eur Acad Dermatol Venereol. 2024 May.

. 2024 May;38(5):e374-e376.

doi: 10.1111/jdv.19783. Epub 2024 Jan 12.

¹ Department of Surgical Science, University of Turin, Turin, Italy.
² State Research Center of Dermatovenereology and Cosmetology, Moscow, Russian Federation.
³ Sechenov First Moscow State Medical University, Moscow, Russian Federation.
⁴ Department of Public Health and Infectious Diseases, Sapienza University, Rome, Italy.

No abstract available

References

1. Koneczny I, Yilmaz V, Lazaridis K, Tzartos J, Lenz TL, Tzartos S, et al. Common denominators in the immunobiology of IgG4 autoimmune diseases: what do glomerulonephritis, pemphigus vulgaris, myasthenia gravis, thrombotic thrombocytopenic purpura and autoimmune encephalitis have in common? Front Immunol. 2021;11:605214.
1. Tavakolpour S. Pemphigus trigger factors: special focus on pemphigus vulgaris and pemphigus foliaceus. Arch Dermatol Res. 2018;310:95–106.
1. Irrgang P, Gerling J, Kocher K, Lapuente D, Steininger P, Habenicht K, et al. Class switch toward noninflammatory, spike‐specific IgG4 antibodies after repeated SARS‐CoV‐2 mRNA vaccination. Sci Immunol. 2023;8:eade2798.
1. Petti S, Arduino PG. New‐onset pemphigus vulgaris and pemphigus foliaceus following COVID‐19 infection and vaccination, systematic review of case reports and a causal hypothesis. J Eur Acad Dermatol Venereol. 2023;37:e1256–e1260.
1. Vandenbroucke JP, Pearce N. Case‐control studies: basic concepts. Int J Epidemiol. 2012;41:1480–1489.